Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

NCT07341191 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

NETWORK

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Sonrotoclax
BIOLOGICAL: CAR-T Cell Therapy

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]